60 questions about SCLC with Dr. Greg Kalemkerian Part 2 скачать в хорошем качестве

60 questions about SCLC with Dr. Greg Kalemkerian Part 2

In this expert interview, Dr. Greg Kalemkerian shares practical, real-world guidance on managing small cell lung cancer (SCLC) — from frontline therapy to relapse, supportive care, and emerging research. ✅ Key Takeaways ✔️ Limited-Stage SCLC: Concurrent platinum–etoposide chemoradiation remains standard, with durvalumab consolidation, now part of care for eligible patients. ✔️ Extensive-Stage SCLC: Carboplatin/etoposide plus atezolizumab or durvalumab followed by maintenance immunotherapy is the standard approach. ✔️ Myelosuppression Management: Routine G-CSF is not required upfront; dose adjustments are often preferred. Use growth factors selectively for high-risk or complicated cases. ✔️ Neuropathy Prevention: Prefer carboplatin over cisplatin in higher-risk patients; early switch if neuropathy develops. ✔️ Brain Management: MRI surveillance is often preferred over PCI in extensive-stage disease; careful patient selection is critical. ✔️ Paraneoplastic Syndromes: SIADH occurs in ~5–10%; neurologic syndromes are rare but clinically significant. Avoid immunotherapy in autoimmune neurologic conditions (e.g., Lambert-Eaton). 00:00 Introduction & Overview of Small Cell Lung Cancer 00:45 Myelosuppression Management & G-CSF Use 03:30 Chemotherapy-Induced Neuropathy (Cisplatin vs Carboplatin) 05:45 Managing Dyspnea & Radiation Role 07:20 PCI, Brain Surveillance & Cognitive Effects 08:50 Palliative Care Integration in SCLC 11:25 Mental Health Support in SCLC 12:45 End-of-Life Decision Making 14:40 Communicating Prognosis & Goals of Care 16:45 Combined Small Cell & Non-Small Cell Histology 18:30 EGFR Transformation & Treatment Strategy 20:40 Large Cell Neuroendocrine Carcinoma 23:20 Treatment Advances in the Last 5 Years 25:15 Surgery vs Chemoradiation in Early-Stage Disease 27:15 PCI in Early-Stage & Ongoing Trials 28:40 Consolidative Thoracic Radiation & Immunotherapy 31:10 Targeted Therapy Challenges in SCLC 33:05 Tumor Mutational Burden & Biomarkers 34:00 Why Targeted Therapy Has Been Difficult in SCLC 36:00 BCL-2 Targeting & Clinical Trials 37:55 Circulating Tumor DNA (ctDNA) 39:45 Telemedicine in SCLC Care 42:10 AI & Machine Learning in Oncology 44:45 Paraneoplastic Syndromes in SCLC 49:10 SIADH Supportive Care 51:30 Immunotherapy Contraindications (Autoimmune Neurologic Disease) 52:25 Most Rewarding Aspects of Treating SCLC 55:00 Balancing Optimism with Prognosis 58:50 Treatment Summary: Limited vs Extensive Stage #SmallCellLungCancer #SCLC #LungCancer #ThoracicOncology #MedicalOncology #CancerTreatment #Immunotherapy #Chemotherapy #RadiationOncology #DLL3 #Tarlatamab #Lurbinectedin #OncologyEducation #CancerResearch #OncologyUpdate SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information. Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research. 🔔 New videos every day! 💻 Visit us at https://oncodaily.com/